Appointment of Broker

Syntopix Group plc

("Syntopix" or "the Company")

Appointment of Broker

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicinal and consumer healthcare markets, today announces that the Company has appointed XCAP Securities Plc as the Company's Broker with immediate effect.

Zeus Capital Limited remains the Company's Nominated Adviser.

- Ends -

For further information, please contact:

Media enquiries:

Notes to editors

Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour.

The Group has 12 granted UK patents, a robust research pipeline, and a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity.

Syntopix' shareholders include IP Group plc, The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.